Document is current

Article History

Received: 22 March 2024

Accepted: 18 July 2024

First Online: 30 August 2024

Competing interests

: M.V. has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi and Tricog Health; has speaker engagements with AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics; and participates on clinical trial committees for studies sponsored by AstraZeneca, Bayer, Galmed, Occlutech, Novartis and Impulse Dynamics. A.S.B. has received research grant support to his institution from the National Institutes of Health/National Heart, Lung, and Blood Institute, the National Institutes of Health/National Institute on Aging, the American College of Cardiology Foundation and the Centers for Disease Control and Prevention and has received consulting fees from Sanofi Pasteur and Novo Nordisk. B.L.C. has received consulting fees from Amgen, Cardurion, Corvia, Myokardia and Novartis. C.S.L. has received speaker fees and served on advisory boards for GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, Takeda and Valneva. L.K. has received speaker fees from Novo Nordisk, Novartis, AstraZeneca, Boehringer Ingelheim and Bayer. S.D.S. has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Eli Lilly, Mesoblast, MyoKardia, National Institutes of Health/National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi, Theracos and US2.AI and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros and Puretech Health. T.B.-S. has served as chief investigator of the Sanofi-financed NUDGE-FLU trial, the Sanofi-financed DANFLU-1 trial and the Sanofi-financed DANFLU-2 trial; served as steering committee member of the Amgen-financed GALACTIC-HF trial, the Boston Scientific–financed LUX-Dx TRENDS trial and the Boehringer Ingelheim–financed EASi-KIDNEY trial; served on advisory boards for Sanofi, GlaxoSmithKline, Amgen and CSL Squirus; received speaker honoraria from Bayer, GlaxoSmithKline, Novartis, GE Healthcare and Sanofi; consulted for Novo Nordisk, IQVIA and Parexel; and received research grants from GE Healthcare, Sanofi, Boston Scientific, AstraZeneca and Novo Nordisk. All other authors declare no competing interests.